Fang Liu, MD, PhD, is a Hematologist practising and conducting research at the Chengdu Military General Hospital, Chengdu, Sichuan, China.
Speaking on cellular therapies and HSCT
Dr Liu’s main research interests lie in developing cellular targeted therapies for the treatment of hematologic malignancies, particularly in the relapsed/refractory setting.
Dr Liu is the Principal Investigator of the early Phase I trial (NCT04156256) exploring CD123-CD33 compound chimeric antigen receptor (CAR) immunotherapy within relapsed/refractory, high risk hematologic malignancies. She is also the Principal Investigator of a Phase I study (NCT04162340) investigating CD4-specific CAR-T cells for relapsed/refractory T-cell malignancies.
Dr Liu has recently been involved in a study exploring the combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) as frontline therapy for high-risk diffuse large B-cell lymphoma (DLBCL).